The Claim
In patients with glycogen storage disease type Ia, plasma and urine contain elevated levels of lactate/pyruvate ratios, acylcarnitines, and TCA cycle intermediates, indicating systemic metabolic derangements beyond impaired glucose production.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Patients with glycogen storage disease type Ia have abnormal levels of specific metabolic compounds in their blood and urine, showing that their entire metabolism is disrupted in ways that go beyond just trouble making glucose.
See the scientific wording
In patients with glycogen storage disease type Ia, markers of mitochondrial dysfunction—including elevated lactate/pyruvate ratios, acylcarnitines, and TCA cycle intermediates—are detectable in plasma and urine, suggesting systemic metabolic derangements beyond impaired glucose production.
A genetic defect blocks the breakdown of glucose-6-phosphate, causing it to build up and force excess pyruvate into lactate production. This overwhelms the mitochondria, which become damaged over time and cannot use pyruvate for energy. As a result, lactate and other metabolic byproducts pile up in the blood and urine, even when blood sugar is normal.
What the research says
1 studyEven when their blood sugar is normal, people with GSDIa have dangerously high levels of lactate in their blood, which means their cells’ energy factories (mitochondria) aren’t working right—even though they’re not low on sugar.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.